Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer treatments like targeted therapy and immunotherapy have advanced treatment, but immune evasion remains a challenge.
• DNA-damage response inhibitors (DDRis) are emerging as agents that can boost anti-tumor immune responses.

Purpose of the Study:

• To review the molecular effects of DDR inhibitors on cancer cells and the immune system.
• To explore the rationale for combining DDR inhibitors with immunotherapy for enhanced cancer treatment.
• To discuss biomarkers and novel immunotherapies for future combination strategies.

Main Methods:

• Literature review of studies on targeted DNA-damage response inhibitors (DDRis).
• Analysis of molecular consequences of DDR inhibition, including tumor cell death and immune engagement.
• Review of clinical data and mechanistic rationale for DDRi and immunotherapy combinations.

Main Results:

• DDR inhibitors can induce tumor cell death and potentiate anti-tumor immune responses.
• These effects are particularly noted in tumors with defects in DNA repair genes (e.g., BRCA1/2, ATM).
• Combinations of DDRis and immunotherapy show potential for enhanced tumor control.

Conclusions:

• Targeted DDR inhibition modulates the tumor microenvironment and enhances immune response.
• Pairing DDR inhibitors with immunotherapy is a promising strategy for next-generation cancer treatment.
• Biomarker identification and novel immunotherapy approaches are crucial for optimizing combination therapies.